Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.
Tao Luan, Suneng Fu, Weiting Liu et al.
✦ AI-curated · Sources linked
Case in brief
A patient with HER2-mutant lung adenocarcinoma developed resistance and severe interstitial lung disease after antibody-drug conjugate (ADC) therapy. A human organoid drug sensitivity test was used to assess treatment options. The organoid results indicated sensitivity to sunvozertinib and lack of efficacy of the ADC, with reported maximum IC₅₀ values of 0.28 and 2.96, respectively. The report presents organoid testing as a means of identifying a potential salvage therapy after resistance to ADC treatment.
What made this case unusual
The case combined ADC resistance and severe interstitial lung disease with organoid testing that suggested a different treatment option, linking functional drug response to the clinical challenge of salvage therapy.
Diagnostic / clinical pearl
In HER2-mutant lung adenocarcinoma with treatment resistance, organoid drug sensitivity testing may help assess candidate therapies when genomic profiling alone does not establish functional drug response.